Donald Picker Ph.D. - Chief Executive Officer
Dr. Picker received his Ph.D. in Organic Chemistry from SUNY Albany. He has spent his entire career as a senior executive in the pharmaceutical industry and has decades of experience in all aspects of drug development. He is also an experienced entrepreneur and has raised over $75 million of investment capital for various biotechnology ventures. Dr. Picker and his team at Johnson Matthey were responsible for the successful development of Carboplatin, currently one of the world’s leading cancer drugs with annual sales of over $500 million. He filed the first successful anti-sense IND with the FDA while Executive VP of Research and Development at Genta, where he founded the cancer program. Dr. Picker was CEO of Synergy Pharmaceuticals which merged into Callisto Pharmaceuticals. At Callisto he was Executive VP of Research & Development where he was responsible for licensing their two lead cancer platforms and bringing these cancer drugs into Phase I and Phase II development. Dr. Picker was also President and COO of Tapestry Pharmaceuticals where he built the clinical development group and brought its lead cancer drug into Phase II clinical trials.

Albert Henry, MBA - Director
Mr. Henry brings over 30 years of health care business, management, and finance experience to Sinapis Pharma. He holds a BS in Civil Engineering from Bradley University and an MBA in Finance and Marketing from J.L. Kellogg Graduate School of Business at Northwestern University in Chicago. Mr. Henry started his career with Citibank in New York as a commercial lending officer, and was subsequently responsible for all commercial and industrial loans at 42 Citibank branches as well as the National Division. Subsequently, he founded his Wall Street Investment Banking business, Henry & Co., which specialized in middle market M & A transactions and institutional research. After 10 years as an investment banker, he was Chairman, CEO and CFO of 8 medical device and health care service companies. In 1982, he founded Henry Venture Funds and over 20 years was lead institutional investor in 12 health care and biotech startups with a combined market capitalization of $ 1.5 billion. He later became Adjunct Professor of Finance at Kellogg Graduate School of Management, Northwestern University where he created and taught a highly successful course on Venture Capital. He is an author and published a textbook on venture investing entitled The Good, The Bad and The Living Dead.

Howard Chandler, Jr MD – Chairman, Founder
Dr. Chandler is a practicing neurosurgical oncologist and entrepreneur. He founded and served from 1995 – 2006 as Chairman of the Montana Neuroscience Institute Foundation, a biomedical research organization that fosters NIH-funded neuroscience research at the University of Montana and Saint Patrick’s Hospital in Missoula, MT. Dr. Chandler is founder and chairman of InterWest Health, LLC, a privately-held Montana-headquartered managed care company that has grown into the largest managed care organization in the region with over 15,000 providers in 7 states. He helped found and served from 1998 - 2008 on the Board of Directors of Alliance Healthcard, Inc, a publicly traded health care company headquartered in Norman, Oklahoma. He founded and serves on the Board of Directors of Treasure State Bank, Inc, a publicly traded bank in Missoula, MT. Dr. Chandler received a B.S. in Chemistry from the University of the South, an M.D. from Wake Forest University, and completed Neurosurgery residency at the University of Florida.

David Poulsen, PhD – Chief Scientific Officer, Inventor
Dr. Poulsen is a Research Associate Professor in the Department of Pharmaceutical Sciences at The University of Montana in Missoula, MT. After earning a Bachelor’s degree in Microbiology at Brigham Young University, Poulsen obtained his Masters and Ph.D. degrees in Molecular Virology from the University of Delaware. Following the completion of his doctoral degree, he trained at the National Institutes of Health as an Intramural Training Research Award (ITRA) fellow in the Laboratory of Persistent Viral Diseases (National Institute of Allergy and Infectious Disease, Rocky Mountain Laboratories). Following his training at the NIH, Dr. Poulsen served a second post-doctoral fellowship in the CNS Gene Therapy Center at Thomas Jefferson University in Philadelphia, PA. In 2001, Poulsen joined the Montana Neuroscience Institute as a Research Assistant Professor in the Department of Pharmaceutical Sciences at the University of Montana and as a Translational Research Scientist with St. Patrick Hospital and Health Sciences Center.